IP Library › Granted Patent US 11,202,811
Granted Patent B2
US 11,202,811 · App. 15/759,915 · Granted Dec 21, 2021

Lactobacillus having various functions, and use thereof

Inventors: Dong Hyun Kim (Seoul, KR); Myung Joo Han (Seoul, KR)
A61K35/747A23L33/135A61K35/745A61K36/48A61P25/28C12N1/205A23V2002/00A23Y2220/43A23Y2220/67A61K2035/115C12R2001/225C12R2001/25
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,202,811
App. No.
15/759,915
Granted
Dec 21, 2021
Kind
B2
Abstract

The present invention provides novel Lactobacillus sp. strains, novel Bifidobacterium sp. strains, or lactic acid bacteria mixtures thereof, which are isolated from kimchi or human feces. A certain Lactobacillus sp. strain or certain Bifidobacterium sp. strain according to the present invention is isolated from kimchi or human feces, and thus is highly safe, and has various physiological activities such as antioxidant activity, β-glucuronidase inhibitory activity, lipopolysaccharide (LPS) production inhibitory activity or tight junction protein expression-inducing activity. Accordingly, a certain Lactobacillus sp. strain, certain Bifidobacterium sp. strain or mixture thereof according to the present invention may be used as a functional food or medicinal material useful for the prevention, alleviation or treatment of intestinal damage, liver injury, allergic disease, inflammatory disease, or obesity.

Claims (6)

1. A method of treating one or more diseases selected from a group consisting of intestinal damage, liver injury, allergic disease and inflammatory disease, comprising administering a composition comprising Lactobacillus plantarum LC27 (accession number: KCCM 11801P), a culture thereof, a lysate thereof or an extract thereof to a subject,

wherein the intestinal damage is intestinal permeability syndrome; the liver injury is selected from a group consisting of hepatitis, fatty liver and liver cirrhosis; the allergic disease is selected from a group consisting of atopic dermatitis, asthma, pharyngitis and chronic dermatitis and wherein the inflammatory disease is selected from a group consisting of gastritis, gastric ulcer, colitis and arthritis; and

wherein the Lactobacillus plantarum LC27 has antioxidant activity, beta-glucuronidase inhibitory activity, lipopolysaccharide (LPS) production inhibitory activity and tight junction protein expression-inducing activity.

2. The method according to claim 1 , wherein the Lactobacillus plantarum LC27 comprises a 16S rDNA nucleotide sequence of SEQ ID NO: 5.

3. The method according to claim 1 , wherein the composition further comprises one or more lactic acid bacteria selected from a group consisting of Lactobacillus brevis CH23 (accession number: KCCM 11762P), Bifidobacterium longum CH57 (accession number: KCCM 11764P), Lactobacillus plantarum LC5 (accession number: KCCM 11800P) and Bifidobacterium longum LC67 (accession number: KCCM 11802P).

4. The method according to claim 1 , wherein the composition further comprises Bifidobacterium longum LC67 (accession number: KCCM 11802P), a culture thereof, a lysate thereof or an extract thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: KIM, DONG HYUN; HAN, MYUNG JOO
To: UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY; NAVIPHARM CO, LTD.
Reel/Frame 045819/0142 →
Priority Claims (2)
KR 10-2015-0130124 · Sep 15, 2015 · national
KR 10-2016-0005018 · Jan 15, 2016 · national
Continuity (1)
Related Publication 20190030097A1 · Jan 31, 2019